CymaBay Therapeutics

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The clinical-stage liver and other chronic disease specialist published its first-quarter results, which included a business update. The company's net loss was deeper than analysts expected.

Why CymaBay Therapeutics Stock Nose-Dived This Week

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why

CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Officer Charles McWherter - Chief Scientific Officer and President, Research and Development Lewis Stuart - Chief Commercial Officer Dan Menold - Vice President, Finance Conference Call Participants Yasmeen Rahimi - Piper Sandler Steve Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Patrick Dolezal - LifeSci Capital Julian Harrison - BTIG Andy Hsieh - William Blair Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Operator Good day, ladies and gentlemen, and welcome to CymaBay's First Quarter 2023 Financial Results and Business Update Conference Call.

CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Call Transcript

Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer

CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.

CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023

Today, we shine the spotlight on CymaBay Therapeutics, Inc., whose stock has had a big rally in 2023. The company is advancing its lead asset Seladelpar towards approval and recently signed a licensing deal in Japan, but cash burn remains a concern.

CymaBay Therapeutics: Slow But Steady Progress

Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that seasoned biopharma executive Harish Shantharam, CFA has joined the company as Chief Financial Officer.

CymaBay Names Harish Shantharam Chief Financial Officer

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology:

CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

Asure Software

In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E.

Four Potential Breakout Stocks For The Rest Of The Week - Asure Software (NASDAQ:ASUR), CymaBay Therapeutics (NASDAQ:CBAY)

NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.

CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going

Remitly Global

RxSight

United Wholesale Mortgage

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

4 Best Breakout Stocks to Buy Now for Superlative Returns

The consensus price target hints at a 40.3% upside potential for CymaBay Therapeutics Inc. (CBAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know

CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - President, Research & Development and Chief Scientific Officer Lewis Stuart - Chief Commercial Officer Dan Menold - Vice President, Finance Conference Call Participants Yasmeen Rahimi - Piper Sandler Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Jay Olson - Oppenheimer Julian Harrison - BTIG Operator Good day ladies and gentlemen and welcome to CymaBay's Fourth Quarter and Full-Year 2022 Financial Results and Business Update Conference Call.

CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Call Transcript

Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET

CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update.

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.

CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

CymaBay caught a strong bid in early FY23 after advising its collaboration with Kaken Pharma in Japan. Its seladelpar compound has potential to create a medical breakthrough in primary biliary cholangitis.

CymaBay: Long Term Is Constructive With Potential Seladelpar Conversion

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $7.00 per share before underwriting discounts and commissions. In addition, CymaBay sold pre-funded warrants to purchase 2,142,857 shares of common stock in the offering, at a public offering price of $6.9999 per underlying share before underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants were offered by CymaBay. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share. The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by CymaBay. CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,821,428 shares of its common stock at the public offering price per share less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Alset EHome International

Fate Therapeutics

Hall of Fame Resort & Entertainment

Century Therapeutics

P3 Health Partners Inc

Avidity Biosciences

Summit Therapeutics

Trean Insurance Group

Viking Therapeutics

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Advances strategy to partner seladelpar for PBC outside U.S.

CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

100% technical buy signals. 13 new highs and up 84.95% in the last month.

News for CymaBay Therapeutics Stock (CBAY)